A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer

Completed

Conditions studied: Advanced Ovarian Cancer

In brief

This study will collect the data from existing patient medical records at US cancer centers. The study will include patients with BRCAwt ovarian cancer who have been prescribed first line (1L) olaparib maintenance treatment.

Key facts

Study ID

NCT05775549

Run by

AstraZeneca

People needed

24

Starts

2023-07-10

Expected to finish

2023-10-27

Last updated by the study team

2024-09-20

Who can join

Age: 18 and older, up to 130. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female adult, age ≥ 18 years
• BRCAwt AOC diagnosed with any approved BRCA test
• Has documented HRD status based on available test results
• Received 1L olaparib maintenance monotherapy following platinum chemotherapy
• Patients must have been treated with platinum-based chemotherapy at first-line

You may not qualify if…

• Received another poly adenosine diphosphate ribose polymerase (PARP) inhibitor or bevacizumab before or while prescribed olaparib
• Participation in an interventional clinical study

Where it is running

• Research Site — Tampa, Florida, United States
• Research Site — Shreveport, Louisiana, United States
• Research Site — Annapolis, Maryland, United States
• Research Site — Baltimore, Maryland, United States
• Research Site — New York, New York, United States
• Research Site — Charlotte, North Carolina, United States
• Research Site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.